Form 4: SOPHIA GENETICS SA: Insider Sells Shares

SOPHIA GENETICS SA reports a Form 4 filing detailing a transaction by Chief Scientific Officer Zhenyu Xu.

Summary

• Zhenyu Xu, Chief Scientific Officer of SOPHiA GENETICS SA, sold 4,000 ordinary shares on June 15, 2026.
• The sale was executed as part of a pre-arranged trading plan under Rule 10b5-1(c).
• The shares were sold at a weighted average price of $5.0141, with individual transactions ranging from $4.90 to $5.13.
• Following this transaction, Zhenyu Xu beneficially owns 622,280 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents a routine insider transaction executed under a pre-arranged trading plan, with no immediate indication of significant company performance changes.

Negatives

• Insider selling of shares can sometimes be perceived negatively by the market, although this sale was conducted under a pre-arranged trading plan.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The execution of this sale under a Rule 10b5-1 plan suggests a pre-determined strategy for managing personal holdings, which is a common practice to avoid insider trading concerns.

Stakeholder Impact

• Shareholders: The sale is conducted under a Rule 10b5-1 plan, which is designed to mitigate concerns about insider trading. The impact on share price is likely minimal given the pre-planned nature and the relatively small volume of shares sold compared to the insider's total holdings.

Key Dates

Keywords

SOPH, SOPHiA GENETICS SA, Form 4, Insider Trading, Rule 10b5-1, Share Sale, Beneficial Ownership